An experimental mRNA cancer-fighting vaccine jointly developed by Moderna and Merck has reportedly succeeded in a Phase II trial. According to the companies, melanoma survivors who received the vaccine in combination with immunotherapy were 44% less likely to have their cancer return or to die than those who only took…
